

Organized by:



 #MPITT2024



Meet the professor  
in thoracic tumors:

**SANJAY POPAT**  
**MPITT-BCN2024**

**October 8<sup>th</sup>, 2024**  
**16:00h - 19:15h LIVE STREAMING**

**Scientific Coordinators:**

**Dr. Enriqueta Felip**

Hospital Universitari Vall d'Hebron, Barcelona

**Dr. Noemi Reguart**

Hospital Clínic, Barcelona



Meet the professor  
in thoracic tumors:

**SANJAY POPAT**  
MPITT-BCN2024

October 8<sup>th</sup>, 2024  
16:00h - 19:15h LIVE STREAMING

#MPITT2024

16:00h - 16:05h **Welcome**

Dr. **Enriqueta Felip**, Hospital Universitari Vall d'Hebron, Barcelona  
Dr. **Noemi Reguart**, Hospital Clínic, Barcelona

16:05h - 17:30h **SESSION 1: Evolution of therapy for early-stage NSCLC**

**Chairpersons:**

Dr. **Luis Paz-Ares**, Hospital Universitario 12 de Octubre, Madrid  
Dr. **Dolores Isla**, Hospital Clínico Universitario Lozano Blesa, Zaragoza

16:05h - 16:25h **MASTER LECTURE: Progress and prospects of perioperative IO in early-stage NSCLC**

Prof. **Sanjay Popat**, The Royal Marsden Hospital, London, United Kingdom

16:25h - 16:40h **Weighing options for "potentially resectable" T4 & N2 disease**

Dr. **Mariano Provencio**, Hospital Puerta de Hierro, Madrid

16:40h - 16:55h **Biomarkers & surrogates to personalize IO strategies in early-stage NSCLC**

Dr. **Ernest Nadal**, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona

16:55h - 17:10h **New advances with targeted therapies in early-stage**

Dr. **Margarita Majem**, Hospital de la Santa Creu i Sant Pau, Barcelona

17:10h - 17:30h **Discussion**

17:40h - 19:15h **SESSION 2: Second-line NSCLC, Opportunities & challenges**

**Chairpersons:**

Dr. **Enric Carcereny**, Institut Català d'Oncologia - Hospital Universitari Germans Trias i Pujol, Badalona

Dr. **Silvia Catot**, Hospital Althaia Xarxa Assistencial Universitària de Manresa, Barcelona

17:40h - 17:55h **Understanding the mechanisms of IO-resistance**

Dr. **Ignacio Gil-Bazo**, Instituto Valenciano de Oncología, Valencia

17:55h - 18:10h **Novel IO strategies and combinations to overcome resistance**

Dr. **Rosario García Campelo**, Complejo Hospitalario Universitario de A Coruña

18:10h - 18:25h **Updates on results with Antibody Drug Conjugates (ADCs)**

Dr. **Pilar Garrido**, Hospital Universitario Ramón y Cajal, Madrid

18:25h - 18:40h **Future directions for ADCs (biomarkers, bispecifics, new drug conjugates, sequence and resistance)**

Dr. **Eduarne Arriola**, Hospital del Mar, Barcelona

18:40h - 18:55h **Targeted Therapies for KRAS + NSCLC**

Dr. **Jordi Remon**, Gustave Roussy, Paris, France

18:55h - 19:15h **Discussion**

19:15h - 19:20h **Closing Remarks**

Dr. **Enriqueta Felip**, Hospital Universitari Vall d'Hebron, Barcelona

Dr. **Noemi Reguart**, Hospital Clínic, Barcelona